Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Mar 31, 2016 12:24pm
175 Views
Post# 24715643

RE:RE:RE:Richmond club presentation

RE:RE:RE:Richmond club presentationI watched/listened to the Richmond presentation and my opinion is that Don was referring to a "fixed dose combination" and not a "6 dose combination" of Crestor with Apabetalone. If there are multiple doses, I presume this refers to the statin portion of the combo. Six different statin doses seems excessive; but possibly 2 or 3 (low, medium, high dose Crestor).

The profit benefit of this would be that Crestor is soon to become very cheap once it comes off patent. So to make a combo pill of Apabetalone with Crestor would be quite cheap.

And if BonM proves that 1) Apabetalone reduces MACE in diabetics, and 2) Crestor is superior to other statins such as lipitor, then the combo pill may become the new standard of care for diabetics as opposed to statin alone.

Just my opinion.

BearDownAZ
Bullboard Posts